Super Biologics gets $135.6 million term loan, revolving credit line

By Marisa Wong

Los Angeles, Dec. 1 – Super Biologics Inc. obtained $135.6 million of financing with the healthcare finance business of CIT acting as lead arranger.

The financing, which consists of a term loan and a revolving line of credit, will be used to refinance existing debt, fund a shareholder dividend, provide working capital and support growth initiatives.

Based in Sharon Hill, Pa., Superior Biologics is a provider of specialty pharmacy and home infusion therapy services to patients with chronic illnesses.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.